ES2175350T3 - Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso. - Google Patents

Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.

Info

Publication number
ES2175350T3
ES2175350T3 ES97905450T ES97905450T ES2175350T3 ES 2175350 T3 ES2175350 T3 ES 2175350T3 ES 97905450 T ES97905450 T ES 97905450T ES 97905450 T ES97905450 T ES 97905450T ES 2175350 T3 ES2175350 T3 ES 2175350T3
Authority
ES
Spain
Prior art keywords
production
optionally replaced
ring
melatonine
union
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97905450T
Other languages
English (en)
Other versions
ES2175350T5 (es
Inventor
Shigenori Ohkawa
Osamu Uchikawa
Kohji Fukatsu
Masaomi Miyamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27286462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2175350(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2175350T3 publication Critical patent/ES2175350T3/es
Publication of ES2175350T5 publication Critical patent/ES2175350T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

SE PROPORCIONAN UN COMPUESTO DE FORMULA (I), EN LA QUE R SUP,1 ES UN HIDROCARBURO, AMINO O GRUPO HETEROCICLICO OPCIONALMENTE SUSTITUIDO; R 2 ES H O UN GRUPO HIDROCARBURO OPCIO NALMENTE SUSTITUIDO; R 3 ES H O UN HIDROCARBURO O GRUPO HETEROCICLICO OPCIONALMENTE SUSTITUIDO; X ES CHR 4 , NR SUP ,4 , O O S EN LA CUAL R 4 ES H O UN GRUPO HIDROCARBURO OPCIONALMENTE SUSTITUIDO; Y ES C, CH O N; EL ANILLO A ES UN ANILLO DE 5 A 7 ESLABONES OPCIONALMENTE SUSTITUIDO; EL ANILLO B ES UN ANILLO DE BENCENO OPCIONALMENTE SUSTITUIDO Y M ES 1 A 4, O UNA SAL DEL MISMO, UN PROCEDIMIENTO PARA SU PRODUCCION, UN INTERMEDIO PARA LA PRODUCCION Y UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE.
ES97905450T 1996-03-08 1997-03-05 Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso. Expired - Lifetime ES2175350T5 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP8-51491 1996-03-08
JP5149196 1996-03-08
JP18366796 1996-07-12
JP8-183667 1996-07-12
JP2918597 1997-02-13
JP9-29185 1997-02-13

Publications (2)

Publication Number Publication Date
ES2175350T3 true ES2175350T3 (es) 2002-11-16
ES2175350T5 ES2175350T5 (es) 2008-12-16

Family

ID=27286462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97905450T Expired - Lifetime ES2175350T5 (es) 1996-03-08 1997-03-05 Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.

Country Status (19)

Country Link
US (1) US6218429B1 (es)
EP (2) EP0885210B2 (es)
JP (1) JP4358917B2 (es)
KR (1) KR100494214B1 (es)
CN (3) CN100441574C (es)
AT (1) ATE219071T1 (es)
CA (1) CA2241666C (es)
CZ (1) CZ291626B6 (es)
DE (1) DE69713294T3 (es)
DK (1) DK0885210T5 (es)
ES (1) ES2175350T5 (es)
HU (1) HU224220B1 (es)
NO (1) NO322205B1 (es)
NZ (1) NZ330656A (es)
PL (1) PL188093B1 (es)
PT (1) PT885210E (es)
SK (1) SK283970B9 (es)
TW (1) TW562803B (es)
WO (1) WO1997032871A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773798B1 (fr) 1998-01-16 2001-02-02 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1206996C (zh) * 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
CA2382418A1 (en) 1999-08-20 2001-03-01 Shigenori Ohkawa Dihydrobenzofuran derivatives, process for preparing thereof and agents
WO2001013950A1 (en) 1999-08-20 2001-03-01 Takeda Chemical Industries, Ltd. Percutaneous absorption agents
JP4721495B2 (ja) * 1999-08-20 2011-07-13 武田薬品工業株式会社 ジヒドロベンゾフラン誘導体、その製造法及び剤
JP4632499B2 (ja) * 1999-08-26 2011-02-16 武田薬品工業株式会社 鼻粘膜付着マトリックス
PL201229B1 (pl) * 1999-09-08 2009-03-31 Aventis Cropscience Uk Ltd Sposób zmniejszania fitotoksyczności
WO2002040053A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Pharmaceutical preparation containing talc/barium sulfate
CA2650698C (en) * 2000-11-17 2013-05-28 Takeda Pharmaceutical Company Limited Copolyvidone-containing preparation
US6800648B2 (en) * 2001-04-26 2004-10-05 Wyeth Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
TWI400220B (zh) * 2004-09-13 2013-07-01 Takeda Pharmaceutical 光活性胺衍生物的製法
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
MY142214A (en) * 2005-04-04 2010-11-15 Takeda Pharmaceutical Prophylactic or therapeutic agent for depression or anxiety disorder
KR20080027783A (ko) * 2005-06-22 2008-03-28 다케다 야쿠힌 고교 가부시키가이샤 난용성 활성 성분을 함유하는 정제
KR101146807B1 (ko) 2005-07-29 2012-05-21 반다 파마슈티칼즈, 인코퍼레이티드. 각성을 향상시키는 방법
CA2644181A1 (en) * 2006-03-20 2007-09-27 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for irritable bowel syndrome
TWI402261B (zh) * 2006-06-19 2013-07-21 Takeda Pharmaceutical 三環化合物及其醫藥組成物
ATE548371T1 (de) * 2006-12-08 2012-03-15 Takeda Pharmaceutical Tricyclische verbindung und deren medizinische verwendung
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
JP5291470B2 (ja) 2006-12-28 2013-09-18 武田薬品工業株式会社 三環性化合物およびその医薬用途
WO2008106179A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
US8110585B2 (en) 2007-04-26 2012-02-07 Takeda Pharmaceutical Company Limited Bicyclic compound and pharmaceutical use thereof
EP2069320A2 (en) 2007-05-31 2009-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2009060318A2 (en) * 2007-07-12 2009-05-14 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ramelteon and processes for preparation thereof
ES2324849A1 (es) * 2007-10-25 2009-08-17 Ferrer Internacional, S.A. Compuestos de indano.
US7470814B1 (en) * 2007-10-31 2008-12-30 Ferrer Internacional, S.A. Process for the preparation of substituted 7-allyl-6-hydroxy-indanes
US20090281176A1 (en) * 2007-11-01 2009-11-12 Vinod Kumar Kansal Process for the synthesis of ramelteon and its intermediates
WO2009096564A1 (ja) * 2008-01-31 2009-08-06 Takeda Pharmaceutical Company Limited 注意欠陥・多動性障害の予防または治療剤
US8871807B2 (en) 2008-03-28 2014-10-28 Ecolab Usa Inc. Detergents capable of cleaning, bleaching, sanitizing and/or disinfecting textiles including sulfoperoxycarboxylic acids
EP2271616B1 (en) 2008-03-28 2020-11-11 Ecolab USA Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
US12203056B2 (en) 2008-03-28 2025-01-21 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
US8809392B2 (en) 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
JP2011529477A (ja) * 2008-07-30 2011-12-08 フエルレル インターナショナル，ソシエダッド アノニマ １，６−ジヒドロ−２ｈ−３−オキサ−６−アザ−ａｓ−インダセン化合物
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2010055481A1 (en) * 2008-11-14 2010-05-20 Watson Pharma Private Limited Process for the preparation of ramelteon
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
EP2396309A1 (en) 2009-02-12 2011-12-21 LEK Pharmaceuticals d.d. Synthesis of (s)-n-ý2-(1,6,7,8-tetrahydro-2h-indeno-ý5,4-b¨furan-8-yl)ethyl¨propionamide
EP2406242B1 (en) * 2009-03-10 2013-06-05 Industriale Chimica S.R.L. Process for the preparation of ramelteon
EP2243775A1 (en) 2009-04-07 2010-10-27 LEK Pharmaceuticals d.d. Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon
EP2483258A1 (en) 2009-09-29 2012-08-08 Lonza Ltd. Process for preparing 1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-one
AU2010306750B2 (en) * 2009-10-15 2014-11-13 Children's Medical Center Corporation Sepiapterin reductase inhibitors for the treatment of pain
WO2012035303A2 (en) 2010-09-17 2012-03-22 Cipla Limited Et Al A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon
CN102321056B (zh) * 2011-07-29 2014-05-14 宁波人健药业集团股份有限公司 一种合成雷美替胺的方法
CN102391220A (zh) * 2011-10-10 2012-03-28 四川大学 三环乙醇类化合物及其制备方法和用途
US9321664B2 (en) 2011-12-20 2016-04-26 Ecolab Usa Inc. Stable percarboxylic acid compositions and uses thereof
CA2867565C (en) 2012-03-30 2021-01-19 Victor KEASLER Use of peracetic acid/hydrogen peroxide and peroxide-reducing agents for treatment of drilling fluids, frac fluids, flowback water and disposal water
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
WO2014010603A1 (ja) 2012-07-10 2014-01-16 アステラス製薬株式会社 腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物、及び該医薬組成物に含有される化合物のスクリーニング方法
CN103724357B (zh) * 2012-10-11 2016-06-08 中国药科大学 一种3,4-二氢吡喃并[3,2-b]吲哚-2-酮类化合物的合成方法
CN102924410A (zh) * 2012-10-29 2013-02-13 华润赛科药业有限责任公司 一种雷美替胺的制备方法及其中间体
US20140256811A1 (en) 2013-03-05 2014-09-11 Ecolab Usa Inc. Efficient stabilizer in controlling self accelerated decomposition temperature of peroxycarboxylic acid compositions with mineral acids
US8822719B1 (en) 2013-03-05 2014-09-02 Ecolab Usa Inc. Peroxycarboxylic acid compositions suitable for inline optical or conductivity monitoring
US10165774B2 (en) 2013-03-05 2019-01-01 Ecolab Usa Inc. Defoamer useful in a peracid composition with anionic surfactants
ES2694049T3 (es) 2014-01-14 2018-12-17 Astellas Pharma Inc. Compuesto de indol
JP6893476B2 (ja) 2016-01-08 2021-06-23 武田薬品工業株式会社 自閉症スペクトラム障害の予防または治療剤
AU2017205519B2 (en) 2016-01-08 2022-01-27 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for delirium
CR20210551A (es) 2019-05-31 2021-12-14 Ecolab Usa Inc Método de monitoreo de las concentraciones de perácidos mediante medidas de conductividad y composición de perácidos
US12096768B2 (en) 2019-08-07 2024-09-24 Ecolab Usa Inc. Polymeric and solid-supported chelators for stabilization of peracid-containing compositions
CN110776485B (zh) * 2019-11-22 2022-09-30 山东邹平大展新材料有限公司 一种雷美替胺杂质的制备方法
WO2023059546A1 (en) * 2021-10-04 2023-04-13 Psilosterics, Llc Serotonin receptor agonists and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2713636B1 (fr) 1993-12-07 1996-01-05 Adir Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
FR2725985B1 (fr) † 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5661186A (en) 1995-02-24 1997-08-26 Bristol-Myers Squibb Co. Tetralinyl-and indanyl-ethylamides

Also Published As

Publication number Publication date
TW562803B (en) 2003-11-21
DE69713294D1 (de) 2002-07-18
WO1997032871A1 (en) 1997-09-12
EP0885210A1 (en) 1998-12-23
EP0885210B1 (en) 2002-06-12
PL328726A1 (en) 1999-02-15
US6218429B1 (en) 2001-04-17
CA2241666A1 (en) 1997-09-12
NZ330656A (en) 1999-06-29
KR19990087628A (ko) 1999-12-27
DK0885210T5 (da) 2008-10-13
ES2175350T5 (es) 2008-12-16
NO322205B1 (no) 2006-08-28
PT885210E (pt) 2002-09-30
HUP9900616A2 (hu) 1999-06-28
ATE219071T1 (de) 2002-06-15
EP0885210B2 (en) 2008-06-18
CN100441574C (zh) 2008-12-10
PL188093B1 (pl) 2004-12-31
JPH11152281A (ja) 1999-06-08
CZ277598A3 (cs) 1998-12-16
NO983970L (no) 1998-08-28
CA2241666C (en) 2007-11-06
HU224220B1 (hu) 2005-06-28
NO983970D0 (no) 1998-08-28
CN100443480C (zh) 2008-12-17
SK283970B6 (sk) 2004-06-08
HK1087112A1 (zh) 2006-10-06
AU2231897A (en) 1997-09-22
CN1212691A (zh) 1999-03-31
CN1727339A (zh) 2006-02-01
CZ291626B6 (cs) 2003-04-16
SK283970B9 (sk) 2004-10-05
DK0885210T4 (da) 2008-09-08
AU706610B2 (en) 1999-06-17
JP4358917B2 (ja) 2009-11-04
HUP9900616A3 (en) 2002-11-28
KR100494214B1 (ko) 2005-11-25
EP1550655A1 (en) 2005-07-06
SK115098A3 (en) 1999-03-12
CN1900067A (zh) 2007-01-24
DE69713294T2 (de) 2003-02-13
DE69713294T3 (de) 2009-01-15
DK0885210T3 (da) 2002-10-07

Similar Documents

Publication Publication Date Title
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
ECSP941122A (es) Derivados de 5-arilindoles
AR062931A2 (es) Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
ATE175198T1 (de) N-acylierte trizyklische azaheteroringe verwendbar als vasopressin-antagonisten
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
UY26199A1 (es) Nuevos derivados de benceno, un procedimiento para su preparación y las composiciones farmacéuticas que los contienen
ES2113368T3 (es) Antagonistas de serotonina.
ES2037753T3 (es) Compuestos heterociclicos y su preparacion y uso.
ES2171428T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
ES2150039T3 (es) Benzonitrilos como 5-ht agonistas y antagonistas.
ES2165360T3 (es) Cicloalquenos y cicloalcanos 1,3-sustituidos como agentes del sistema nervioso central.
AR021596A1 (es) Compuestos que inhiben la procolageno c-proteinasa.
AR016433A1 (es) Procedimiento para el tratamiento de la impotencia y composiciones.
EA200001039A1 (ru) Кальцилитические соединения
MX9305947A (es) Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
ES2158840T3 (es) Nuevos analogos de adenosina carbociclicos utiles como inmunosupresores.
ES2170759T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
ES2088011T3 (es) Antagonistas de aminoacidos excitadores.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 885210

Country of ref document: ES